Lymphocele Outcomes After Renal Transplantations Performed by an Experienced Surgeon: Is Meticulously Performed Surgery and Experience Adequate to Prevent Lymphocele?

20 February 2024: Original Paper

Nurettin Ay ^1ABCDEF* , Vahhac Alp ^1B , Recai Duymuş ^2BD , Sedat Çetin ^3BD

DOI: 10.12659/AOT.942656

Ann Transplant 2024; 29:e942656

Table 2 Patient, surgical, preoperative, and postoperative variables.

Characteristic	All patients n=315	Nonlymphocele group 233 (74%)	Lymphocele group 82 (26%)	P value
				0.97
Under 18.4	4 (1.2%)	3 (1.3%)	1 (1.2%)
18.5–24.9	217 (68.9%)	159 (68.2%)	58 (70.7%)
25–29.9	56 (17.8%)	43 (18.5%)	13 (15.9%)
30–34.9	33 (10.5%)	25 (10.7%)	8 (9.8%)
35–39.9	4 (1.2%)	3 (1.3%)	1 (1.2%)
Over 40	1 (0.3%)	1 (0.4%)	0
				0.123
Basiliximab	67 (21.3%)	54 (23.2%)	13 (15.9%)
ATG	232 (73.7%)	170 (73%)	62 (75.6%)
No induction	16 (5.1%)	9 (3.9%)	7 (8.5%)
				0.315
TAC+MMF+PRED	302 (95.9%)	223 (95.7%)	79 (96.3%)
CS+MMF+PRED	5 (1.6%)	5 (2.1%)	0
EVE+TAC+PRED	8 (2.3%)	5 (2.1%)	3 (3.7%)
	4 (1.3%)	4 (1.7)	0	0.576
				0.239
0 MM	33 (10.5%)	19 (8.2%)	14 (17.1%)
1 MM	8 (2.5%)	6 (2.6%)	2 (2.4%)
2 MM	49 (15.6%)	34 (14.6%)	15 (18.3%)
3 MM	109 (34.6%)	81 (34.8%)	28 (34.1%)
4 MM	30 (9.5%)	25 (10.7%)	5 (6.1%)
5 MM	53 (16.8%)	43 (18.5%)	10 (12.2%)
6 MM	33 (10.5%)	25 (10.7%)	8 (9.8%)
	1.27±0.86	1.27±0.94	1.26±0.61	0.85
	28 (8.9%)	20 (8.6%)	8 (9.8%)	0.75
BMI – body mass index; ATG – anti-thymocyte globulin; TAC – tacrolimus; MMF – mycophenolate mofetil; PRED – prednisolone; CS – cyclosporine; EVE – everolimus; DGF – delayed graft function.